IPO
-
-
-
-
-
-
-
Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome
-
-
-
-
-
-
-
Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease
-
-
-
-
-
-
-
Akcea Therapeutics (AKCA), Ionis (IONS) Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for Treatment of FCS
-
-
-
-
-
-
-
Akcea Therapeutics Named Among Top 100 Women-Led Businesses in Massachusetts for Second Consecutive Year
-
-
-
-
-
-
-
Akcea (AKCA) and Ionis (IONS) Announce Submission of NDA for Volanesorsen to U.S. FDA
-
-
-
-
-
-
-
Akcea Therapeutics (AKCA) Closes IPO, Reports $50M Private Placement with Novartis Pharma (NVS)
-
-
-
-
-
-
-
Ionis Pharma (IONS) Spinoff Akcea Therapeutics (AKCA) Files IPO
-
118,853 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

